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ABSTRACT
Objective: FloSeal is a thrombin-gelatin hemostatic ma-
trix that is used to obtain hemostasis. There have been
isolated case reports of FloSeal causing bowel obstruc-
tions, requiring surgical intervention. We report 3 cases of
what we believe were FloSeal-induced small bowel ob-
structions (SBO).
Methods: We present a series of small bowel obstructions
after FloSeal use. Our series includes urology, gynecologic
oncology, and general surgery cases at the same institu-
tion where the product was appropriately used and re-
sulted in the same complication.
Results: FloSeal was used for hemostasis in all patients. In
each instance, a small bowel obstruction developed in 7
days to 9 days. All patients were reexplored laparoscopi-
cally and found to have an intense inflammatory reaction
at the site of the FloSeal. The adhesions were lysed and
the obstructions resolved.
Conclusions: Although further study is needed, the com-
mon factor in all these SBOs was a hemostatic agent. In
our and others’ series, the time to SBO was 7 days to 9
days. If an early postoperative SBO occurs after FloSeal is
used, prompt reexploration should be considered.
Key Words: Small bowel obstruction, Hemostatic agents,
FloSeal.
INTRODUCTION
Recent advances in biotechnology have led to the devel-
opment of a range of products designed to prevent intra-
peritoneal adhesions and excessive bleeding. Usually, he-
mostasis can be achieved through conventional means,
such as suturing and electrocautery. But many adjuvants
are available to complement these traditional methods
when they fail or in a situation where they are difficult to
apply. These tools include hemostatic agents that contain
collagen, gelatin, and cellulose products and newer
agents that contain components of the coagulation cas-
cade. These intraoperative hemostatic agents have be-
come increasingly used to control intraoperative bleeding
in conventional surgery. In addition, these products have
been adapted for laparoscopic use and are used more
frequently as the complexity of minimally invasive surgery
expands. When selecting an intraoperative hemostatic
agent, it is important to consider adverse effects and com-
plications due to the use of the agent. Although rare,
adverse effects have been reported with the use of hemo-
static agents, including anemia, atrial fibrillation, infection,
rash, hypotension, respiratory distress, confusion, arrhyth-
mias, thrombi, and fever.1 Recently, isolated cases of small
bowel obstruction (SBO) requiring surgical intervention
have been reported.2,3 These cases have been associated
with the use of FloSeal Matrix Hemostatic Agent (Baxter
International Inc., Deerfield, IL).
We report a multidisciplinary case series of patients who
had FloSeal used and all developed small bowel obstruc-
tions. This is the third case report to our knowledge to
describe this adverse event resulting from FloSeal use.
CASE REPORTS
The first patient was a 46-year-old male who underwent a
laparoscopic-assisted right nephrectomy. Mild hemor-
rhage was noted in the renal bed, and FloSeal was used to
provide hemostasis. The postoperative course was com-
plicated with an SBO by postoperative day (POD) #7. The
patient was taken for a diagnostic laparoscopy and was
found to have intense inflammatory reaction of the small
bowel to the renal bed with a granular material causing a
transition point. This was bluntly taken down, and the
obstruction resolved.
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SCIENTIFIC PAPERThe second patient was a 37-year-old female who un-
derwent a laparoscopic gastric bypass. At the conclu-
sion of the case, FloSeal was used on some bleeding
near the staple line of the jejujejunostomy. On POD#8,
the patient experienced vomiting and intense abdomi-
nal pain. Diagnostic laparoscopy showed bowel ob-
struction with the jejujejunostomy stuck to the anterior
abdominal wall, causing the bowel to kink and ob-
struct. These granular adhesions were taken down and
the obstruction resolved.
The final patient was a 63-year-old female who under-
went a robotic-assisted laparoscopic hysterectomy, ure-
terolysis, and bilateral salpingo-oophorectomy for a be-
nign adnexal mass. At the conclusion of the case,
FloSeal was used on some bleeding near the left pelvic
sidewall. On POD#2, the patient experienced nausea
and vomiting, and the diagnosis of SBO versus ileus
was entertained. By POD#7, it was apparent that the
patient had a bowel obstruction. She was taken to the
operating room for a diagnostic laparoscopy and found
to have the terminal ileum stuck to the left pelvic
sidewall, causing the bowel to kink and obstruct. These
granular adhesions were taken down, and the obstruc-
tion initially resolved, but then recurred. The patient
underwent an exploratory laparotomy on POD#14, and
the same granular adhesions were found and taken
down, resolving the SBO.
DISCUSSION
Laparoscopic surgery is constantly evolving. More com-
plex procedures are being performed, and novel agents
like hemostatic agents are used in these procedures.
These agents are also used in open surgery, but their
utility in laparoscopic surgery is probably more impor-
tant, as the surgeon cannot easily stick a finger or gauze
over an oozing surface. There has also been an increase
in the number of hemostatic agents on the market,
some of which are sold with laparoscopic applicators.
Commonly used agents include oxidized cellulose (Surgi-
cel, Ethicon, Somerville, NJ), gelatin sponges (Gelfoam/
Surgifoam, Ethicon, Somerville, NJ), and microfibrillar col-
lagen (Avitene, Davol, Warwick, RI). All of these agents
are absorbable. Biologic agents include FloSeal, CoSeal,
and bovine thrombin. These various products function
through different pathways but ultimately increase the
body’s ability to activate the clotting cascade and increase
hemostasis. Thombin is a semi-pure cow thrombin that
activates host platelets and fibrin but does have immuno-
logic effects in humans. FloSeal matrix consists of a bo-
vine-derived gelatin matrix component, and a human-
derived thrombin component and needs exposure to
blood to activate. CoSeal is polyethylene glycol glue that
has no obvious biologic or immunologic effect. As men-
tioned previously, some of the adverse events caused by
these agents include anemia, atrial fibrillation, infection,
rash, hypotension, respiratory distress, confusion, arrhyth-
mias, thrombi, fever, and postsurgical immune-mediated
coagulopathy. Small bowel obstruction has only recently
been reported in 2 other case reports, both in the gyne-
cology literature.2,3
Usually, postoperative adhesions are a major source of
morbidity following laparotomy and are the most com-
mon cause of small bowel obstruction in developed coun-
tries.4 Adhesions are fibrous, sometimes vascular bands of
scar tissue that connect normally separated organs or
tissues and are an almost inevitable result of intraperito-
neal surgery.5 In a prospective analysis of patients under-
going laparotomy after a previous abdominal operation,
Menzies and Ellis6 found that 93% of patients had adhe-
sions resulting from their previous surgery, compared to
just 10% of patients undergoing first-time laparotomy.
Previous gynecologic surgery is the second most common
cause of adhesive SBO after colorectal surgery.4,7–9 Even
though postoperative adhesions are the most common
cause of SBO, immediate postoperative bowel stasis in the
presence of prothrombotic agents on gelatin matrix
(FloSeal) is a reasonable cause for these patients’ small
bowel obstruction.
FloSeal Matrix Hemostatic Agent (Baxter International
Inc., Deerfield, IL) is a relatively new thrombin-based
hemostatic adjuvant that is extracted from bovine cor-
neal tissue. It is a dual component system that combines
the contact activation properties of a gelatin matrix with
human thrombin. The gelatin granules swell as they
absorb blood, and fibrin monomers polymerize along
this surface. The result is a hemostatic plug that con-
forms to the shape of the wound. FloSeal requires
premixing, activates factors V, VIII, and XIII, converts
fibrinogen to fibrin, and is applied from a proprietary
syringe. With its paste-like properties and relatively
small applicator syringe, FloSeal is easy to use in lapa-
roscopic surgery. Because the product relies on the
presence of fibrin to become activated, FloSeal will not
work if bleeding is completely absent or if the patient is
deficient in fibrin (about 1/1 million people).
Gelatin-based products (like FloSeal) have been implicated
as a nidus of infection and abscess formation and have been
reported to potentiate bacterial growth. There has also been
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mas in the brain after the use of a gelatin-based product
(Gel-foam, Fibrillar, and FloSeal).1,10,11 Giant cell reaction
mimicking an abscess after cardiac surgery has been re-
ported after Surgicel application.12 There was also a recent
report of a caseating granuloma caused by a hemostatic
agent that was suspected of being a metastatic leiomyosar-
coma.13 This led to an unnecessary laparotomy.
Hobday et al2 report an eosinophilic response causing an
SBO. FloSeal was used to control hemorrhage, and an
SBO resulted on POD #6. Exploration on POD #11 re-
vealed a single area of adhesions associated with the
FloSeal. Thomas and Tawfic3 also reported a case series of
3 patients with postoperative SBO after FloSeal use. Inter-
estingly, they also found an eosinophil-rich inflammatory
response that was consistent with a type 1 hypersensitivity
response. The strength of their report is that they had
resected tissue to examine.
Hoffman et al14 compared adhesion formation by hemo-
static agents in a rat model. The agents studied were
Arista, CoSeal, BioGlue, Tisseel, FloSeal, and Surgicel.
Arista and CoSeal showed limited adhesion formation,
and FloSeal, Tisseel, and Surgicel were not statistically
different in adhesion formation. BioGlue promoted adhe-
sions. Although they did not find that FloSeal increased
adhesions, it was still present at 7 days in the form of the
gelatin matrix. The FloSeal group also showed increased
acute inflammation and collagen fibrosis.
Two important events occur in the early postoperative
period: adhesiogenesis up to 14 days and the early inflam-
matory/healing response. The maximum inflammatory re-
sponse is at 7 days to 10 days. The gelatin matrix is not
completely reabsorbed for 6 weeks. There may be a rela-
tionship between gelatin matrix and the early inflamma-
tory response that could be the causative factor in SBOs
after FloSeal use. Further study is indicated, and it is
incumbent on the producer to study and report these
events.
Although we feel that the hemostatic agent used contrib-
uted to the SBO, there are obviously multiple factors that
can affect adhesiogenesis. A combination of electrocau-
tery and ultrasonic dissection were used in all the cases to
varying degrees. The type and extent of dissection may
have contributed to an increased adhesiogenesis, which
could be a confounding factor in these cases. Also, our
management was of aggressive and relatively early reop-
eration once the diagnosis was made. Some surgeons feel
watchful waiting is more appropriate for SBOs, but we
believe that the clinical picture and a clear transition point
on CT is an indication for operation. The argument can be
made that this is a resorbable material; however, the time
needed to reabsorb the gelatin matrix can extend up to 6
weeks, obviously too long for observation of a bowel
obstruction.
This information was presented to our local Baxter repre-
sentative. We hope that a database of adverse events,
funded by industry, can be created. There are very good
instances to use all the hemostatic agents involved, but
getting a more complete picture of possible adverse out-
comes, and the situations surrounding the outcomes, will
help surgeons become more comfortable at using the right
agent for the right situation. We do not advocate, “throw-
ing the baby out with the bath water,” and think a nation-
wide database would provide even more support for the
use of hemostatic agents.
CONCLUSIONS
Although further study is needed, the common factor in all
these SBOs was a hemostatic agent. In our and others’
series, the time to SBO was 7 days to 9 days. If an early
postoperative SBO occurs after FloSeal is used, prompt
reexploration should be considered.
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